# OnCo record rp2d (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/rp2d/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "rp2d" ;
  schema:name "Recommended phase 2 dose (RP2D)"@en ;
  schema:alternateName "RP2D"@en, "recommended phase 2 dose"@en, "recommended phase II dose"@en, "recommended dose"@en, "recommended dose for expansion"@en, "dose selected"@en, "selected dose"@en, "the dose taken forward"@en, "registrational dose"@en ;
  schema:description "The dose and schedule chosen at the end of a phase 1 trial to test in larger trials, based on safety, blood levels and early signs of activity. It is often, but no longer always, the maximum tolerated dose."@en ;
  schema:url <https://onco.cc/terms/rp2d/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Phase_I_clinical_trial> ;
  schema:citation <https://en.wikipedia.org/wiki/Phase_I_clinical_trial> ;
  onco:related <https://onco.cc/terms/mtd/>, <https://onco.cc/terms/dose-limiting-toxicity/>, <https://onco.cc/terms/dose-escalation-design/>, <https://onco.cc/terms/pharmacokinetics/> ;
  onco:sections <https://onco.cc/fronts/drug-discovery/> ;
  onco:technologies <https://onco.cc/terms/project-optimus/> .